IN2012DE00661A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DE00661A IN2012DE00661A IN661DE2012A IN2012DE00661A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A IN 661DE2012 A IN661DE2012 A IN 661DE2012A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A
- Authority
- IN
- India
- Prior art keywords
- substituted
- hetero
- aminoquinoline
- aryl
- formula
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 4
- -1 cyno Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 abstract 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 1
- ODOPLLNPLYGBPQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one;(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol;1,3,7-trimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 ODOPLLNPLYGBPQ-UHFFFAOYSA-N 0.000 abstract 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000005010 aminoquinolines Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000002390 heteroarenes Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229960001962 mefloquine Drugs 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/028329 WO2013134047A2 (en) | 2012-03-07 | 2013-02-28 | Aminoquinoline derivatives and uses thereof |
| EP21194376.6A EP3971178A1 (en) | 2012-03-07 | 2013-02-28 | Aminoquinoline derivatives and uses thereof |
| ES13758678T ES2899730T3 (es) | 2012-03-07 | 2013-02-28 | Derivados de la aminoquinolina y sus usos |
| PT137586780T PT2822936T (pt) | 2012-03-07 | 2013-02-28 | Derivados da aminoquinolina e suas utilizações |
| US14/382,727 US9567316B2 (en) | 2012-03-07 | 2013-02-28 | Aminoquinoline derivatives and uses thereof |
| IN661DE2012 IN2012DE00661A (en:Method) | 2012-03-07 | 2013-02-28 | |
| EP13758678.0A EP2822936B1 (en) | 2012-03-07 | 2013-02-28 | Aminoquinoline derivatives and uses thereof |
| US15/404,964 US11026943B2 (en) | 2012-03-07 | 2017-01-12 | Aminoquinoline derivatives and uses thereof |
| US17/240,886 US20220008418A1 (en) | 2012-03-07 | 2021-04-26 | Aminoquinoline Derivatives and Uses Thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN661DE2012 IN2012DE00661A (en:Method) | 2012-03-07 | 2013-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DE00661A true IN2012DE00661A (en:Method) | 2015-08-21 |
Family
ID=49117483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN661DE2012 IN2012DE00661A (en:Method) | 2012-03-07 | 2013-02-28 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9567316B2 (en:Method) |
| EP (2) | EP2822936B1 (en:Method) |
| ES (1) | ES2899730T3 (en:Method) |
| IN (1) | IN2012DE00661A (en:Method) |
| PT (1) | PT2822936T (en:Method) |
| WO (1) | WO2013134047A2 (en:Method) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10144932B2 (en) * | 2014-06-06 | 2018-12-04 | Board Of Trustees Of Michigan State University | Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease |
| CN104070943B (zh) * | 2014-07-23 | 2017-10-17 | 万通智控科技股份有限公司 | 一种自编程轮胎压力监测装置及实现方法 |
| WO2016111957A1 (en) * | 2015-01-06 | 2016-07-14 | Albert Einstein College Of Medicine, Inc. | Chloroquinoline triazole compounds, composition and uses |
| EP3260121A4 (en) * | 2015-02-16 | 2018-07-25 | Postech Academy-Industry Foundation | Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient |
| US10329258B2 (en) | 2015-04-30 | 2019-06-25 | University Of Washington | CGAS in systemic lupus erythematosus (SLE) |
| US11426431B2 (en) | 2015-06-15 | 2022-08-30 | Mayo Foundation For Medical Education And Research | Using autologous mesenchymal stem cells to treat multiple system atrophy |
| CN105301126B (zh) * | 2015-10-10 | 2021-02-12 | 大道隆达（北京）医药科技发展有限公司 | 一种托匹司他有关物质的分析方法 |
| JP6861795B2 (ja) | 2016-08-12 | 2021-04-21 | ノブメタファーマ カンパニー リミテッド | アモジアキンおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物 |
| US11612583B2 (en) | 2018-06-21 | 2023-03-28 | Nevada Research & Innovation Corporation | Disease modifying methods for treating neurodegenerative diseases using nootropic agents |
| CN109620971A (zh) * | 2018-12-14 | 2019-04-16 | 昆明医科大学第附属医院 | 一种筛选防治帕金森病药物的方法 |
| MX2021008533A (es) * | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112022003025A2 (pt) * | 2019-08-22 | 2022-05-10 | Biohaven Therapeutics Ltd | Moléculas que se ligam a tdp-43 para o tratamento de esclerose lateral amiotrófica e distúrbios relacionados |
| WO2021087077A1 (en) * | 2019-10-29 | 2021-05-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of autophagy and histone deactylases and uses thereof |
| US20230312510A1 (en) * | 2020-07-07 | 2023-10-05 | The Mclean Hospital Corporation | Compounds and methods for treating neurodegenerative diseases |
| WO2022178338A2 (en) * | 2021-02-20 | 2022-08-25 | Biohaven Therapeutics Ltd. | Small molecules that bind to tdp-43 for the treatment of als and related disorders |
| WO2023159062A2 (en) * | 2022-02-15 | 2023-08-24 | University Of Central Florida Research Foundation, Inc. | Anabolic drugs stimulating type ii collagen production from chondrocytes or their progenitors |
| WO2024049718A2 (en) * | 2022-08-31 | 2024-03-07 | Immunocure Inc. | Quinoline piperazine derivatives, pharmaceutical composition and uses thereof |
| EP4608809A2 (en) * | 2022-10-28 | 2025-09-03 | The United States Government as represented by the Department of Veterans Affairs | 4-aminoquinolines for treatment of multidrug resistant malaria |
| WO2025024311A2 (en) * | 2023-07-21 | 2025-01-30 | Icahn School Of Medicine At Mount Sinai | G9a/glp inhibitors and methods of use |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3126384A (en) * | 1961-05-26 | 1964-03-24 | X-quinolyl-aminoalkylamino | |
| NL106667C (en:Method) | 1961-12-29 | 1900-01-01 | ||
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4487761A (en) | 1982-04-05 | 1984-12-11 | Merck & Co., Inc. | Dopamine β-hydroxylase inhibitors |
| US4992459A (en) | 1983-04-12 | 1991-02-12 | Smithkline Beecham Corporation | Dopamine-β-hydroxylase inhibitors |
| US4906668A (en) | 1984-08-23 | 1990-03-06 | Georgia Tech Research Corporation | Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions |
| US4634711A (en) | 1985-08-02 | 1987-01-06 | Smithkline Beckman Corporation | Pyridylalkyl imidazole-2-thiols |
| US4719223A (en) | 1985-10-31 | 1988-01-12 | Smithkline Beckman Corporation | Imidazolethiol dopamine-beta-hydroxylase inhibitors |
| US4743613A (en) | 1986-04-08 | 1988-05-10 | Smithkline Beckman Corporation | Ester prodrugs of dopamine-β-hydroxylase, inhibitors, composition containing them, and method of using them to inhibit dopamine-β-hydroxylase activity |
| US5189052A (en) | 1986-05-06 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | Thione dopamine beta hydroxylase inhibitors |
| US4810800A (en) | 1986-05-06 | 1989-03-07 | Merrell Dow Pharmaceuticals Inc. | Novel imidazole dopamine beta hydroxylase inhibitors |
| US4761415A (en) | 1986-08-28 | 1988-08-02 | Smithkline Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
| US4749717A (en) | 1987-01-08 | 1988-06-07 | Smithkline Beckman Corporation | Dopamine-beta-hydroxylase inhibitors |
| US4762850A (en) | 1987-03-24 | 1988-08-09 | Smithkline Beckman Corporation | Dopamine-beta-hydroxylase inhibitors |
| US4859779A (en) | 1987-03-24 | 1989-08-22 | Smithkline Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
| US4835154A (en) | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
| US4798843A (en) | 1987-07-09 | 1989-01-17 | Smithkline Beckman Corporation | 2-mercaproimidazole dopamine-β-hydroxylase inhibitors |
| US4839371A (en) | 1987-09-17 | 1989-06-13 | Smithkline Beckman Corporation | 3-aralkyl-2-mercaptoyridines as dopamine-β-hydroxylase inhibitors |
| US4935438A (en) | 1987-12-29 | 1990-06-19 | Smithkline Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
| US4882348A (en) | 1987-12-29 | 1989-11-21 | Smithkline Beckman Corporation | 2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitors |
| US4876266A (en) | 1987-12-31 | 1989-10-24 | Smithkline Beckman Corporation | 1-aralkyl-2-mercaptoimidazolines as DBH inhibitors |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US4935449A (en) | 1988-08-04 | 1990-06-19 | Merrell Dow Pharmaceuticals Inc. | N-2,3-butadienyl tri- and tetraaminoalkane derivatives |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5100912A (en) | 1990-05-14 | 1992-03-31 | Syntex (U.S.A.) Inc. | Bis(benzylpyrrolidine) derivatives as dopamine agonists |
| US5108899A (en) | 1989-10-31 | 1992-04-28 | Exoxemis, Inc. | Chemiluminescence assay of in vivo inflammation |
| US6559186B1 (en) | 1990-02-26 | 2003-05-06 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
| CN1046723C (zh) | 1993-04-06 | 1999-11-24 | 艾博特公司 | 四环化合物、含有它们的药物组合物及其用途 |
| US5550139A (en) | 1994-01-03 | 1996-08-27 | The Wichita State University | Serine protease inhibitors |
| US5925567A (en) | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
| ES2171911T3 (es) | 1996-10-18 | 2002-09-16 | Wisconsin Alumni Res Found | Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos. |
| US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| UA71951C2 (en) | 1999-04-01 | 2005-01-17 | Pfizer Prod Inc | Pyrimidines as sorbitol dehydrogenase inhibitors, a pharmaceutical composition containing them, intermediate compounds and a method for the preparation of intermediate compound |
| MXPA01011000A (es) | 1999-04-30 | 2003-06-30 | Slil Biomedical Corp | Analogos de poliaminas conformacionalmente restringidos como terapias para enfermedades. |
| BR0010700A (pt) | 1999-04-30 | 2002-02-13 | Slil Biomedical Corp | Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata |
| US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
| IL153864A0 (en) | 2000-08-02 | 2003-07-31 | Slil Biomedical Corp | Cyclic polyamine compounds and methods for the preparation thereof |
| WO2003012040A2 (en) | 2001-07-27 | 2003-02-13 | Baylor College Of Medecine | Mutant nurr1 gene in parkinson's disease |
| US6818772B2 (en) | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| WO2003070244A1 (en) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagonist of melanin concentrating hormone and their uses |
| JP2005537247A (ja) * | 2002-06-27 | 2005-12-08 | シエーリング アクチエンゲゼルシャフト | 置換されたキノリンｃｃｒ５受容体アンタゴニスト |
| US7899888B2 (en) * | 2002-06-28 | 2011-03-01 | Oracle America, Inc. | Runtime versioning of information processing systems |
| US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| WO2005004794A2 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| CN101466380A (zh) * | 2006-02-16 | 2009-06-24 | 麦克莱恩医院 | 治疗帕金森病的方法和组合物 |
| WO2008036374A2 (en) * | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| WO2009148659A2 (en) * | 2008-03-05 | 2009-12-10 | Georgetown University | Antimalarial quinolines and methods of use thereof |
| WO2010059738A1 (en) | 2008-11-18 | 2010-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Differentiation of stem cells into dopaminergic cells |
| WO2010065932A1 (en) | 2008-12-05 | 2010-06-10 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
-
2013
- 2013-02-28 IN IN661DE2012 patent/IN2012DE00661A/en unknown
- 2013-02-28 US US14/382,727 patent/US9567316B2/en active Active
- 2013-02-28 WO PCT/US2013/028329 patent/WO2013134047A2/en active Application Filing
- 2013-02-28 EP EP13758678.0A patent/EP2822936B1/en active Active
- 2013-02-28 EP EP21194376.6A patent/EP3971178A1/en active Pending
- 2013-02-28 PT PT137586780T patent/PT2822936T/pt unknown
- 2013-02-28 ES ES13758678T patent/ES2899730T3/es active Active
-
2017
- 2017-01-12 US US15/404,964 patent/US11026943B2/en active Active
-
2021
- 2021-04-26 US US17/240,886 patent/US20220008418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013134047A2 (en) | 2013-09-12 |
| EP3971178A1 (en) | 2022-03-23 |
| US20220008418A1 (en) | 2022-01-13 |
| US9567316B2 (en) | 2017-02-14 |
| ES2899730T3 (es) | 2022-03-14 |
| WO2013134047A3 (en) | 2013-10-31 |
| EP2822936B1 (en) | 2021-09-08 |
| EP2822936A4 (en) | 2016-04-20 |
| US20150023930A1 (en) | 2015-01-22 |
| EP2822936A2 (en) | 2015-01-14 |
| US20170209441A1 (en) | 2017-07-27 |
| US11026943B2 (en) | 2021-06-08 |
| PT2822936T (pt) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DE00661A (en:Method) | ||
| BR112015014678A2 (pt) | lactamas fundidas com arila e heteroarila | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| EP3670496A3 (en) | Acc2 inhibitors | |
| Ferretti et al. | Synthesis of symmetrically substituted 3, 3-dibenzyl-4-hydroxy-3, 4-dihydro-1H-quinolin-2-ones, as novel quinoline derivatives with antibacterial activity | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| PH12015502038A1 (en) | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | |
| MY165730A (en) | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
| PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| PH12020550905A1 (en) | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives | |
| TN2009000342A1 (en) | Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors | |
| MX394421B (es) | Derivados de piridona policiclica sustituida y profarmaco de los mismos | |
| IN2014CN03976A (en:Method) | ||
| MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
| MX2013006925A (es) | Compuestos de anillo indeno-fusionados. | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| PH12015501571A1 (en) | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline | |
| EA201591105A1 (ru) | ПИРИМИДО[4,5-b]ХИНОЛИН-4,5-(3H,10H)-ДИОНЫ В КАЧЕСТВЕ СУПРЕССОРОВ НОНСЕНС МУТАЦИЙ | |
| MX2017014661A (es) | Proceso para la preparacion de triazinas. | |
| MX2017003238A (es) | Metodo para preparar 2'-o-fucosil-lactosa. | |
| MX361733B (es) | Derivados antibacterianos del 2h-indazol. | |
| EA201692305A1 (ru) | Антибактериальные хиназолин-4(3н)-оновые производные | |
| MY156525A (en) | 2,5,7-substituted oxazolopyrimidine derivatives |